Deutsche Märkte schließen in 3 Stunden 33 Minuten

Ipsen S.A. (IPN.PA)

Paris - Paris Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
66,65-3,35 (-4,79%)
Ab 1:42PM MEZ. Markt geöffnet.

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92650
33 1 58 33 50 00

BrancheDrug Manufacturers—Specialty & Generic

Leitende Angestellte

Mr. David LoewCEO & DirectorN/AN/A1967
Mr. Aymeric Le ChatelierExec. VP & Group CFON/AN/A1969
Dr. Aidan MurphyExec. VP of Technical OperationsN/AN/A1966
Ms. Eugenia LitzVP of Investor RelationsN/AN/AN/A
Mr. Francois GarnierExec. VP & Gen. CounselN/AN/A1962
Mr. Regis MulotExec. VP & Chief HR OfficerN/AN/A1966
Mr. Stephan GagneHead of New Tokyo OfficeN/AN/AN/A
Ms. Dominique LaymandExec. VP of Ethics & Social Responsibility OfficerN/AN/A1954
Mr. Benoit HennionExec. VP of Consumer HealthcareN/AN/A1976
Ms. Dominique BeryExec. VP of Strategy & TransformationN/AN/A1971
Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.


Ipsen S.A. operates as a biopharmaceutical company worldwide. The company offers drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, and Mucodyne. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Corporate Governance

Ipsen S.A.s ISS Governance QualityScore, Stand 3. Dezember 2020, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 7, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.